Skip to content

Released May 12, 2026, before the open

10-Q filed May 12, 2026, 42 days after period end · 0001628280-26-034204

Q1 2026 · 10-Q
Revenue—
Net Income-$20.74MN/M vs Q1 2025N/M vs Q4 2025
EPS Diluted-$0.33N/M vs Q1 2025no prior Q4 2025 on file
Operating Income-$21,149,000N/M
Operating Cash Flow-$24,128,000N/M
Free Cash Flowderived-$24,128,000N/M

What the release said

The release

Same quarter

MetricQ1 2026Q1 2025Q1 2024Q1 2023
Net Income-$20.74M-$28.80M-$14.87M-$11.31M
EPS Diluted-$0.33-$0.48-$0.25-$0.28

The same fiscal quarter, prior years. Thaler holds no estimates to compare against.

Acumen Pharmaceuticals, Inc. · CIK 1576885 · Engraved from SEC EDGAR